A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX

Inclusion Criteria:

- Body weight
- Active moderate to severe rheumatoid arthritis (DAS28 >/=4.4) according to the revised
1987 ACR criteria at screening and baseline (prior to treatment on Day 1)

- Currently receiving oral MTX for at least 24 weeks and on a stable oral dose of at
least 15 mg/week for at least 6 weeks prior to treatment (Day 1), with the following
exception: a stable dose of at least 10 mg/week is allowed for participants with a
body weight <50 kg or calculated glomerular filtration rate (or creatinine clearance)
<60 milliliters per minute (mL/min)

- History of parenteral (SC or intramuscular [IM]) MTX is allowed, but not within 6
weeks prior to treatment (Day 1). Participants must not have a documented, clinically
significant intolerance to oral MTX and must be receiving oral MTX at a dose of 15
mg/week for at least 6 weeks prior to treatment (Day 1)

- Participants who have received one prior anti-tumor necrosis factor (TNF) must have
discontinued etanercept, infliximab, certolizumab, adalimumab, or golimumab for at
least 6 months prior to screening

- Oral corticosteroids must have been for at least 25 out of 28 days prior to treatment (Day 1)

- Participants receiving treatment on an outpatient basis

Exclusion Criteria:

- Documented medical history of significant intolerance to oral MTX >/=15 mg/week

- Participants receiving other (non-MTX) disease modifying anti-rheumatic drugs (DMARDs)
within 8 weeks of screening

- Previous treatment with abatacept, rituximab, tofacitinib, or anakinra

- Treatment with parenteral corticosteroids within 4 weeks prior to treatment

- Previous treatment with cell-depleting therapies or alkylating agents

- Previous treatment with TCZ

- Major surgery (including joint surgery) within 8 weeks prior to screening or planned
major surgery during the study

- Rheumatic autoimmune disease other than rheumatoid arthritis

- Non-rheumatic active autoimmune diseases (for example, inflammatory bowel diseases,
psoriasis, multiple sclerosis)

- Prior history of or current inflammatory joint disease other than rheumatoid arthritis

- Functional Class IV according to the revised (1987) ACR criteria for rheumatoid
arthritis

- History of severe allergic or anaphylactic reactions to human, humanized, or murine
monoclonal antibodies

- Evidence of significant uncontrolled concomitant diseases; uncontrolled disease states
where flares are commonly treated with oral or parenteral corticosteroids

- Active current or history of recurrent infection, or any major episode of infection
requiring hospitalization or treatment with intravenous antibiotics within 4 weeks
prior to screening or oral antibiotics within 2 weeks prior to screening

- Active tuberculosis requiring treatment within the previous 3 years

- History of or currently active primary or secondary immunodeficiency

- Pregnant or breast-feeding women

- Positive for hepatitis B or hepatitis C infection

- For potential MRI substudy participants: the presence of any metal-containing device
or object in the body